Platelets News and Research

RSS

UCSF scientists identify characteristics of progenitor cells

University of California San Francisco scientists have identified characteristics of a family of daughter cells, called MPPs, which are the first to arise from stem cells within bone marrow that generate the entire blood system. The researchers said the discovery raises the possibility that, by manipulating the fates of MPPs or parent stem cells, medical researchers could one day help overcome imbalances and deficiencies that can arise in the blood system due to aging or in patients with specific types of leukemia.

19 Jun 2015

Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Two medical researchers from the Children's Hospital of Michigan and the Wayne State University School of Medicine have published the results of a nearly 10-year investigation that identified a key gene mutation that can trigger acute lymphoblastic leukemia, or ALL, and several other types of cancer.

18 Jun 2015

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).

15 Jun 2015

Researchers show how a new drug speeds tissue regeneration in animal models

The concept sounds like the stuff of science fiction: take a pill, and suddenly new tissues grow to replace damaged ones. Researchers at Case Western Reserve and UT Southwestern Medical Center this week announced that they have taken significant steps toward turning this once-improbable idea into a vivid reality.

12 Jun 2015

Blood research could improve treatment for injured soldiers on the battlefield

Blood research conducted by biomedical engineers from The University of Texas at San Antonio College of Engineering, in collaboration with the Blood Research Program of the U.S. Army Institute of Surgical Research, could change the way injured soldiers are treated on the battlefield.

4 Jun 2015

LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

Blood clots often form when lipid-rich plaques on the inner surface of arteries rupture and platelets aggregate at the site of injury. Cardiologists from Ludwig-Maximilians-Universitaet in Munich have now compared the effects of two new platelet aggregation inhibitors.

4 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.

30 May 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

Hunter Hayes partners with American Red Cross to save lives through blood donation

Multi-instrumentalist and singer/songwriter Hunter Hayes is partnering with the American Red Cross to help saves lives through blood donation.

30 May 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly and Company announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

29 May 2015

Rapid-deployment plasma protocol helps treat trauma victims faster in the ER

Traumatic injury is the leading cause of death among people under age 45, but if trauma physicians could deliver plasma to these injury victims within minutes of their arrival in the emergency room, more of them would stand a better chance of survival.

29 May 2015

Verax Biomedical obtains FDA clearance to expand use of Verax Platelet PGD test

Verax Biomedical today announced that the company has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The new FDA clearance makes the Verax Platelet PGD test the only rapid test on the market cleared by the FDA to check every commonly distributed platelet type in the United States.

27 May 2015

Cardiology researchers uncover new evidence that relates to increased risk of stroke

Cardiology researchers at The Queen Elizabeth Hospital have uncovered new evidence that relates to patients with new onset atrial fibrillation (AF) and their increased risk of stroke.

20 May 2015

Regular use of aspirin may slow the progression of early emphysema, new research shows

Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.

18 May 2015

Quest Diagnostics launches genomic test service that aids in diagnosis for myeloid neoplasms

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that includes acute myeloid leukemia (AML), the most common form of adult acute leukemia, as well as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs).

From Quest Diagnostics 7 May 2015

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association.

7 May 2015

Platelets News and Research

UCSF scientists identify characteristics of progenitor cells

Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

Researchers show how a new drug speeds tissue regeneration in animal models

Blood research could improve treatment for injured soldiers on the battlefield

LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Hunter Hayes partners with American Red Cross to save lives through blood donation

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Rapid-deployment plasma protocol helps treat trauma victims faster in the ER

Verax Biomedical obtains FDA clearance to expand use of Verax Platelet PGD test

Cardiology researchers uncover new evidence that relates to increased risk of stroke

Regular use of aspirin may slow the progression of early emphysema, new research shows

Quest Diagnostics launches genomic test service that aids in diagnosis for myeloid neoplasms

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms